BridgeBio Oncology Therapeutics (BBOT) Stock Forecast & Price Target

Compare

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BBOT Analyst Ratings

Strong Buy

3 Buy

0 Hold

0 Sell

Based on 3 analysts giving stock ratings to

BridgeBio

Oncology Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BBOT Stock 12 Month Forecast

Average Price Target

$23.00

▲(132.32% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for BridgeBio Oncology Therapeutics in the last 3 months. The average price target is $23.00 with a high forecast of $25.00 and a low forecast of $21.00. The average price target represents a 132.32% change from the last price of $9.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","26":"$26","13.25":"$13.25","17.5":"$17.5","21.75":"$21.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,13.25,17.5,21.75,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.43,11.55076923076923,12.67153846153846,13.792307692307691,14.913076923076922,16.033846153846152,17.154615384615383,18.275384615384617,19.396153846153844,20.516923076923078,21.637692307692305,22.75846153846154,23.87923076923077,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.43,11.396923076923077,12.363846153846154,13.330769230769231,14.297692307692309,15.264615384615386,16.231538461538463,17.198461538461537,18.165384615384617,19.13230769230769,20.099230769230772,21.066153846153846,22.033076923076923,{"y":23,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.43,11.243076923076924,12.056153846153846,12.86923076923077,13.682307692307692,14.495384615384616,15.30846153846154,16.121538461538464,16.934615384615384,17.747692307692308,18.560769230769232,19.373846153846152,20.18692307692308,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.35,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.42,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.59,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.5,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.5,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.7,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.05,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.86,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.85,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.72,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.64,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.43,"date":1754006400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.43,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$25.00

Average Price Target$23.00

Lowest Price Target$21.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Nierengarten

Wedbush

$25

Buy

152.53%

Upside

Reiterated

08/18/25

Wedbush Sticks to Their Buy Rating for BridgeBio Oncology Therapeutics (BBOT)

Biren Amin

Piper Sandler

$21

Buy

112.12%

Upside

Initiated

08/15/25

BridgeBio Oncology initiated with an Overweight at Piper SandlerBridgeBio Oncology initiated with an Overweight at Piper Sandler

Eric Schmidt FCA

Cantor Fitzgerald

―

Buy

―

Initiated

08/13/25

BridgeBio Oncology initiated with an Overweight at Cantor FitzgeraldBridgeBio Oncology initiated with an Overweight at Cantor Fitzgerald

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Nierengarten

Wedbush

$25

Buy

152.53%

Upside

Reiterated

08/18/25

Wedbush Sticks to Their Buy Rating for BridgeBio Oncology Therapeutics (BBOT)

Biren Amin

Piper Sandler

$21

Buy

112.12%

Upside

Initiated

08/15/25

BridgeBio Oncology initiated with an Overweight at Piper SandlerBridgeBio Oncology initiated with an Overweight at Piper Sandler

Eric Schmidt FCA

Cantor Fitzgerald

―

Buy

―

Initiated

08/13/25

BridgeBio Oncology initiated with an Overweight at Cantor FitzgeraldBridgeBio Oncology initiated with an Overweight at Cantor Fitzgerald

Stocks with the Highest Top Analyst Consensus in the General Sector

xxx

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BridgeBio Oncology Therapeutics

1 Month

xxx

Success Rate

1/1 ratings generated profit

Average Return

+1.10%

initiated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +1.10% per trade.

3 Months

xxx

Success Rate

1/1 ratings generated profit

Average Return

+1.10%

initiated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +1.10% per trade.

1 Year

Eric Schmidt FCACantor Fitzgerald

Success Rate

1/1 ratings generated profit

Average Return

+1.10%

initiated a buy rating 27 days ago

Copying Eric Schmidt FCA's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +1.10% per trade.

2 Years

xxx

Success Rate

1/1 ratings generated profit

Average Return

+1.10%

initiated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +1.10% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BBOT Analyst Recommendation Trends

Rating

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BBOT has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BBOT average Analyst price target in the past 3 months is 23.00.

Each month's total comprises the sum of three months' worth of ratings.

BBOT Financial Forecast

No data currently available

BBOT Earnings Forecast

Currently, no earnings data available.

No data currently available

BBOT Sales Forecast

Currently, no sales data available.

BBOT Stock Forecast FAQ

What is BBOT’s average 12-month price target, according to analysts?

Based on analyst ratings, BridgeBio Oncology Therapeutics’s 12-month average price target is 23.00.

What is BBOT’s upside potential, based on the analysts’ average price target?

BridgeBio Oncology Therapeutics has 132.32% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BBOT a Buy, Sell or Hold?

BridgeBio Oncology Therapeutics has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is BridgeBio Oncology Therapeutics’s price target?

The average price target for BridgeBio Oncology Therapeutics is 23.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $21.00. The average price target represents 132.32% Increase from the current price of $9.9.

What do analysts say about BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of BBOT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

BridgeBio Oncology Therapeutics (BBOT) Stock Forecast & Price Target

BBOT Analyst Ratings

BBOT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BridgeBio Oncology Therapeutics

BBOT Analyst Recommendation Trends

BBOT Financial Forecast

BBOT Earnings Forecast

BBOT Sales Forecast

BBOT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts